Parul Jindal, MD
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,093 of the $4,676 with a category attached, or 87.5%. It is spread thinly across 39 manufacturers, the largest accounting for just 17.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,917 and has fallen 85.8% since, to $271 in 2025.
Across 194 payments — averaging $24.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$801
- AbbVie$625
- Medtronic$476
- UCB, Inc.$325
- AstraZeneca$289
- SK Life Science, Inc.$283
- plus $2K from 33 others
What the payments were for
- Travel & lodging$2505%
- Food & beverage$4,09388%
- Education$3337%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 45 | $801 |
| AbbVie(2 entities) | 23 | $625 |
| Medtronic | 5 | $476 |
| UCB, Inc. | 16 | $325 |
| AstraZeneca | 11 | $289 |
| SK Life Science, Inc. | 13 | $283 |
| Lilly USA, LLC | 14 | $228 |
| Tanabe Pharma America, Inc. | 4 | $161 |
| Eisai Inc. | 4 | $161 |
| Greenwich Biosciences, Inc. | 3 | $136 |
| Neurocrine Biosciences, Inc. | 5 | $122 |
| Supernus Pharmaceuticals, Inc. | 6 | $91 |
| Avanir Pharmaceuticals, Inc. | 4 | $79 |
| Novartis | 3 | $67 |
| Biogen | 3 | $66 |
| Amneal Pharmaceuticals LLC | 3 | $65 |
| Averitas Pharma Inc. | 1 | $58 |
| Livanova USA, Inc. | 3 | $57 |
| Akcea Therapeutics, Inc. | 2 | $51 |
| Pfizer | 3 | $48 |
| Hospira, Inc. | 2 | $48 |
| EMD Serono, Inc. | 2 | $45 |
| Genentech USA, Inc. | 2 | $43 |
| Acadia Pharmaceuticals Inc | 2 | $37 |
| Sanofi | 1 | $31 |
| Argenx US, Inc. | 1 | $29 |
| Octapharma USA, Inc. | 1 | $29 |
| Biohaven Pharmaceuticals, Inc. | 1 | $26 |
| Bristol Myers Squibb | 1 | $25 |
| Lundbeck LLC | 1 | $23 |
| Adamas Pharmaceuticals, Inc. | 1 | $22 |
| Impel Pharmaceuticals Inc. | 1 | $21 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $19 |
| GE HealthCare | 1 | $18 |
| Catalyst Pharmaceuticals, Inc. | 1 | $17 |
| Acorda Therapeutics, Inc | 1 | $16 |
| MDD US Operations, LLC | 1 | $13 |
| Avion Pharmaceuticals | 1 | $13 |
| Amgen | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,676 in reported general payments places this provider in the 70th percentile of 105 neurology providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AustedoDeutetrabenazine | 32 | $230,184 |
| IngrezzaValbenazine Tosylate | 20 | $162,247 |
| Austedo XrDeutetrabenazine | 25 | $156,218 |
| Aimovig AutoinjectorErenumab-Aooe | 59 | $56,121 |
| NuplazidPimavanserin Tartrate | 12 | $56,104 |
| Nurtec OdtRimegepant Sulfate | 44 | $55,203 |
| NeuproRotigotine | 43 | $49,745 |
| Lacosamide | 50 | $13,303 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 391 | $13,031 |
| Emgality PenGalcanezumab-Gnlm | 13 | $10,017 |
| RytaryCarbidopa/Levodopa | 11 | $10,001 |
| Sumatriptan Succinate | 84 | $5,512 |
| Levetiracetam | 88 | $3,786 |
| Primidone | 137 | $3,586 |
| Gabapentin | 211 | $3,549 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo, Austedo Xr | $801 | $386,40257 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $122 | $162,24720 claims |
| Acadia Pharmaceuticals IncNuplazid | $37 | $56,10412 claims |
| PfizerNurtec Odt | $48 | $55,20344 claims |
| UCB, Inc.Neupro | $325 | $49,74543 claims |
| Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide | $65 | $11,74325 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 105 neurology providers in Nebraska.
Other neurology in Omaha
- Chad WhyteOmaha$647K
- Scott GoodmanOmaha$377K
- Rana ZabadOmaha$276K
- Deepak MadhavanOmaha$189K
- Pamela SantamariaOmaha$90K
- Peter SohOmaha$60K
- Kiel WoodwardOmaha$32K
- Pierre FayadOmaha$24K
- Jonathan MoravekOmaha$19K
- Erin SmithOmaha$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.